Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”) filed a Next Day Disclosure Return on 7 September 2026 detailing an on-market share buyback executed the same day.

Key Transaction Data • Volume repurchased: 70,000 H shares • Price range: HKD 16.74–16.83 per share • Volume-weighted average price: HKD 16.79 • Total consideration: HKD 1.18 million

Capital Structure After the Buyback • Issued shares (excluding treasury): reduced from 540.42 million to 540.35 million • Treasury shares: increased from 11.52 million to 11.59 million • Total issued shares (including treasury): unchanged at 551.94 million • Reduction in free-float proportion: 0.01% of pre-repurchase shares

Repurchase Mandate Status • Mandate granted: 16 June 2026, authorising up to 54.10 million shares • Cumulative repurchases under mandate: 621,500 shares, representing 0.11% of issued shares on the mandate date • 30-day moratorium on new share issues or treasury share sales effective until 7 October 2026, in accordance with Hong Kong Listing Rules

Regulatory Compliance Fosun Pharma confirmed the transaction complied with Main Board Rule 10.06 and that no material changes have arisen from the explanatory statement in its 11 May 2026 circular.